Folie 1 - Translumina

More documents

Recommendations

Info

Aim of ISAR-TEST-2 Study to compare the anti-restenotic efficacy of: polymer-free probucol+rapamycin-eluting stent (Dual-DES) with permanent polymer rapamycin-eluting stent (Cypher) and permanent polymer zotarolimus-eluting stent (Endeavor) in patients with coronary artery disease
Inclusion Criteria ‣ “De novo” lesions in native coronary arteries ‣ Written informed consent Exclusion Criteria ‣ Left main lesion ‣ Cardiogenic shock ‣ Comorbidities with a life expectancy < 12 months ‣ Contraindication to aspirin, limus agents, probucol, stainless steel, thienopyridines ‣ Pregnancy Patient Selection
Page 1 and 2: A Polymer-Free Dual Drug-Eluting St
Page 3 and 4: Background Long-term polymer residu
Page 5 and 6: Background Previous experience with
Page 7: Background Probucol is a potent lip
Page 11 and 12: Study DES Types • Probucol+rapamy
Page 13 and 14: Statistical Analysis Pre-specified
Page 15 and 16: Data are percentage or mean ± stan
Page 17 and 18: Data are percentage; percentages ma
Page 19 and 20: Primary Endpoint: binary angiograph
Page 21 and 22: QCA Measurements at FU Cypher (n=34
Page 23 and 24: Clinical Follow-Up at 1 year Incide
Page 25 and 26: Conclusions (2) ‣ The efficacy of

Folie 1 - Translumina

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?